Chia-Kai Chu, MD
Ophthalmology · Houston, TXNPI 1356684674
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,697 of the $4,397 with a category attached, or 84.1%. 18 manufacturers reported payments, led by AbbVie at 43.7% of the total.
Across 155 payments — averaging $28.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$762
- Aerie Pharmaceuticals, Inc.$356
- Bausch & Lomb Americas Inc.$339
- Mentor Worldwide LLC$284
- Bausch & Lomb, A Division Of Bausch Health US, LLC$178
- plus $558 from 12 others
Across 1 payment — averaging $10,154 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$10K
What the payments were for
- Consulting fees$70016%
- Food & beverage$3,69784%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $1,921 |
| Alcon | 31 | $762 |
| Aerie Pharmaceuticals, Inc. | 7 | $356 |
| Bausch & Lomb Americas Inc. | 18 | $339 |
| Mentor Worldwide LLC | 2 | $284 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $178 |
| Novartis | 7 | $145 |
| Thea Pharma Inc. | 5 | $99 |
| Amgen(2 entities) | 3 | $59 |
| Akorn Operating Company LLC | 3 | $56 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| Sight Sciences, Inc. | 1 | $32 |
| Glaukos Corporation | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Akorn, Inc. | 1 | $23 |
| Travere Therapeutics, Inc. | 2 | $19 |
| AstraZeneca | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$825
- MENTOR MemoryGel Resterilizable Gel Sizer$284
- Rhopressa$247
- Rocklatan$247
- ReSTOR$141
- Precision 1$125
- LUMIGAN$125
- ALPHAGAN P$125
How this compares
$4,397 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 318 | $177,808 |
| CombiganBrimonidine Tartrate/Timolol | 262 | $119,170 |
| RestasisCyclosporine | 117 | $113,057 |
| RhopressaNetarsudil Mesylate | 212 | $100,755 |
| VyzultaLatanoprostene Bunod | 106 | $53,904 |
| Alphagan PBrimonidine Tartrate | 94 | $36,387 |
| RocklatanNetarsudil Mesylat/Latanoprost | 78 | $32,378 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 129 | $26,928 |
| TyrvayaVarenicline Tartrate | 20 | $25,243 |
| Brimonidine Tartrate | 441 | $22,244 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 88 | $22,206 |
| XiidraLifitegrast | 16 | $22,129 |
| ZioptanTafluprost/Pf | 48 | $21,592 |
| Brinzolamide | 101 | $19,496 |
| Latanoprost | 1,706 | $19,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,921 | $446,421791 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $356 | $133,133290 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $339 | $76,033122 claims |
| AlconSimbrinza, Azopt | $762 | $32,092110 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $16 | $25,24320 claims |
| Akorn, Inc.Zioptan | $23 | $21,59248 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $178 | $2,91918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.